Search Results

EliA RNA Pol III is intended for the in vitro semi-quantitative measurement of IgG antibodies directed to RNA polymerase III (RNA Pol III) in human serum as an aid in the diagnosis of systemic sclerosis (diffuse form) in conjunction with other laboratory and clinical findings. EliA RNA Pol III uses the EliA IgG method.

EliA RNA Pol III is a semi-quantitative solid-phase fluoroenzymeimmunoassay, for the determination of autoantibodies against RNA polymerase III. The EliA RNA Pol III test System is fully integrated and automated system which comprises of assay-specific reagents, EliA method-specific reagents, and general reagents.

Here's a breakdown of the acceptance criteria and study information for the EliA RNA Pol III device, based on the provided text:

Acceptance Criteria and Device Performance

Study Details

2. Sample Size and Data Provenance for the Test Set:

• Test Set (Method Comparison with Predicate Device):
  • Sample Size: 193 patient serum samples.
  • Data Provenance: Not explicitly stated, but includes 126 samples with a diagnosis of SSc. The context suggests these are clinical samples.
• Test Set (Clinical Sensitivity and Specificity):
  • Sample Size: 596 clinically defined serum samples.
  • Data Provenance: Clinically defined samples from patients with various diagnoses, including Systemic Sclerosis (diffuse and limited forms), and various control diseases/conditions (e.g., Celiac disease, Crohn's disease, SLE, RA, bacterial/viral infections). The text does not specify country of origin or if prospective/retrospective; however, "clinically defined serum samples" typically implies retrospective collection with known diagnoses.
• Test Set (Assay Cut-Off):
  • Sample Size: 70 apparently healthy blood donor samples and 17 target disease (Systemic Sclerosis, diffuse) samples.
  • Data Provenance: "apparently healthy blood donor samples" and "target disease samples" (Systemic Sclerosis, diffuse). The text explicitly mentions "sera from Caucasian, African American, Hispanic and Asian population obtained from a blood bank" for the frequency distribution, which likely overlaps with the "apparently healthy blood donor samples" used for cut-off establishment.

3. Number of Experts and Qualifications for Ground Truth (Test Set):

• Number of Experts: Not specified.
• Qualifications of Experts: Not specified. The wording "clinically defined serum samples with a diagnosis" implies that the diagnoses used as ground truth were established clinically by medical professionals, but their specific roles, number, or years of experience are not detailed.

4. Adjudication Method (Test Set):

• Adjudication Method: Not specified. The diagnostic labels for the clinical samples are presented as established fact without mention of an adjudication process.

5. Multi-Reader Multi-Case (MRMC) Comparative Effectiveness Study:

• Was an MRMC study done? No. This device is an in-vitro diagnostic (IVD) assay designed for automated measurement of antibodies, not for interpretation by human readers. Therefore, an MRMC comparative effectiveness study regarding human reader improvement with AI assistance is not applicable.

6. Standalone (Algorithm Only) Performance:

• Was a standalone study done? Yes. The entire performance evaluation, including analytical performance, method comparison, and clinical sensitivity/specificity, evaluates the performance of the EliA RNA Pol III assay itself (the "algorithm only" in this context, as it's an automated system) without human interpretation as part of the primary measurement. The results are generated directly by the instrument.

7. Type of Ground Truth Used:

• For Method Comparison: The ground truth was the results from the predicate device, QUANTA LITE RNA POL III ELISA.
• For Clinical Sensitivity and Specificity: The ground truth was clinical diagnosis ("clinically defined serum samples with a diagnosis from patients with systemic sclerosis, diffuse," etc.).
• For Assay Cut-Off: The ground truth was based on apparently healthy blood donors and clinically diagnosed Systemic Sclerosis, diffuse patients.

8. Sample Size for the Training Set:

• Training Set (Assay Cut-Off establishment): This involved 70 apparently healthy blood donor samples and 17 target disease (Systemic Sclerosis, diffuse) samples. While not explicitly called a "training set," these samples were used to "define the cut-off," which is a form of model training/optimization for classification.
• Other "training" data: The document mentions that "New batches of IgG calibrators are compared to a secondary standard (standardized with the IRP) or the IRP directly and adjusted accordingly to meet the correct concentration." This implies a continuous process of calibration and standardization, where previous data/standards (IRP) could be considered a form of "training" for the calibrators. However, a distinct, large-scale training set for an AI/algorithm in the conventional sense is not detailed as this is a chemical assay.

9. How the Ground Truth for the Training Set was Established:

• For Assay Cut-Off establishment: The ground truth for the 70 apparently healthy blood donors means they were confirmed healthy (presumably through standard screening). For the 17 Systemic Sclerosis (diffuse) samples, the ground truth was their clinical diagnosis.
• For Calibrators: The ground truth for calibrators is established through their traceability to the International Reference Preparation (IRP) 67/86 of Human Serum Immunoglobulins A, G and M from WHO.

Ask a specific question about this device

The Hi-Ox® High FiO2 Mask is intended to deliver high inspired oxygen concentrations to patients who require elevated inspired oxygen.

The HI-Ox80 is an oxygen mask to enable patients to inhale high concentrations of oxygen at moderate flow rates of 8 -10 |pm. It is a simple device consisting of a central manifold section where the patient mask, oxygen tubing and an oxygen reservoir bag attach. The triple valving in the manifold directs the oxygen to the patient and acts as an anti-asphyxiation valve removing the need for ventilation holes in the mask itself, thus allowing for delivery of high FiO2's.

Oxygen from the supply is either delivered to the patient via a one-way valve (inhalation valve) or stored temporarily in the oxygen reservoir bag. During exhalation, expired gas is directed to the atmosphere via another one-way valve (exhalation valve). In the event the patient's minute ventilation exceeds the oxygen supply flow rate, a third sequential dilution valve allows ambient air to get drawn into the inspired limb of the manifold eliminating the potential for asphyxiation.

The inhalation and exhalation one way valves are designed to have very low flow resistance (less than 1,5 cmH,O, typically ~ 1.07 cmH2O at flow rates of 60 lpm) to minimize the work of breathing. The sequential dilution valve is specified to be less than 3 cmH2O/U/sec. The oxygen mask is made of a soft material for conformance to the patient's facial contours. Positioning of the manifold connection on the mask minimizes the effective deadspace.

Here's an analysis of the provided text regarding the Hi-Ox® High FiO2 Mask, focusing on acceptance criteria and the study used to demonstrate compliance.

Hi-Ox® High FiO2 Mask - Acceptance Criteria and Supporting Study

1. Table of Acceptance Criteria and Reported Device Performance

2. Sample Size Used for the Test Set and Data Provenance

The document does not explicitly state the sample size for the tests performed. It mentions "experiments conducted using a SensorMedics 229 metabolic measurement system." It does not specify the number of subjects or runs.

The data provenance is not explicitly stated regarding country of origin. The company is SensorMedics Corporation, located in Yorba Linda, CA, USA. This suggests the tests were likely conducted in the USA. The study design appears to be prospective as it describes direct experimentation to measure product performance.

3. Number of Experts Used to Establish the Ground Truth for the Test Set and Qualifications of Those Experts

There is no mention of experts being used to establish a ground truth with regard to the performance metrics (FiO2, flow resistance). The measurements for these criteria seem to be objective, instrument-based readings. For the "work of breathing," subjective testing was performed, but the number or qualifications of individuals providing this feedback are not specified.

4. Adjudication Method for the Test Set

No adjudication method is mentioned as the reported performance seems to be based on direct measurements and objective criteria, not on expert consensus or interpretation requiring adjudication.

5. If a Multi-Reader Multi-Case (MRMC) Comparative Effectiveness Study Was Done, If So, What Was the Effect Size of How Much Human Readers Improve With AI vs Without AI Assistance

This device is not an AI-powered diagnostic or interpretive tool. Therefore, an MRMC comparative effectiveness study involving human readers and AI assistance is not applicable and was not performed.

6. If a Standalone (i.e. algorithm only without human-in-the loop performance) Was Done

This device is a physical medical device (oxygen mask), not an algorithm or software. Therefore, a standalone algorithm-only performance study is not applicable and was not performed.

7. The Type of Ground Truth Used

The ground truth for the performance criteria (FiO2, flow resistance) was based on objective, instrument-based measurements. For the "work of breathing," it was based on subjective patient feedback.

8. The Sample Size for the Training Set

This device does not involve machine learning or AI, so there is no training set and therefore no sample size for such a set.

9. How the Ground Truth for the Training Set Was Established

As there is no training set, this question is not applicable.

Ask a specific question about this device